The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased bleeding risk. We performed a retrospective observational analysis in 181 patients (median age: 67 years) with confirmed HIT treated in routine practice with lepirudin, to identify predictive factors for thrombotic and bleeding complications. Lepirudin was administered at a mean (± standard deviation) dose of 0.06 ± 0.04 mg/kg per hour (compared with a recommended initial dose of 0.15 mg/kg per hour).
INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment occurring with a frequency of 2.6% with unfractionated heparin and 0.2% with lowmolecular-weight heparins. 1 HIT is caused by heparin-dependent antibodies, generally directed towards the complex formed between heparin and platelet factor 4, which induce a prothrombotic state by activating platelets and endothelial cells. lepirudin, administered according to its recommended dosage regimen, reduced by more than 90% the occurrence of new thrombotic events, but at the cost of an increased bleeding risk. [6] [7] [8] Thus, it is possible that this recommended dosage regimen may not be optimal in terms of antithrombotic benefit-to-bleeding risk ratio. To identify predictive factors for thrombotic and bleeding complications, we performed a retrospective observational study in 181 patients with HIT treated in routine practice with lepirudin, focusing in particular on the influence of the lepirudin dosage regimen on the occurrence of these events.
PATIENTS AND METHODS
This was a multicenter, retrospective, observational study in France and Switzerland (Geneva) under the auspices of the French national group of clinical physicians and biologists working
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From in the field of hemostasis and thrombosis (GEHT, Groupe d'Etude sur l'Hémostase et la Thrombose).
Patients
Data of all patients over 16 years with suspected or confirmed HIT who had received lepirudin between December 1997 and December 2004 were collected in 32 centers (see Appendix). HIT diagnosis was confirmed on the basis of clinical or laboratory data by an independent Critical Event Committee (see Appendix).
Data collection
A number of complementary approaches were used to ensure the exhaustiveness of the identification of HIT patients treated with lepirudin during the study period. First, GEHT members were requested to report all cases corresponding to the inclusion criteria. Second, pharmacists of public or private hospitals to which lepirudin had been sold by the various manufacturers of this product (Schering, Aventis, and Pharmion) were contacted by mail and telephone in order to determine the use of each lepirudin batch supplied. Clinical departments to which lepirudin had been delivered were contacted to identify HIT patients in whom this treatment had been used. Finally, all French drug monitoring centers were contacted to obtain the list of patients who had experienced HIT. In each center with potentially eligible patients, a clinical research assistant collected the data using a standardized case report form. All the data were subsequently centralized by the center responsible for data analysis (Centre d'Investigation Clinique, Hôpital Bellevue, Saint-Etienne, France).
Study outcomes
The primary study outcomes were the occurrence of thrombotic and bleeding events while patients were treated with lepirudin. Thrombotic episodes (including amputations) were confirmed on the basis of clinical findings or imaging data (phlebography, duplex
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From ultrasonography, lung scanning, pulmonary angiography or CT scan). Major bleeding was defined as fatal bleeding, bleeding in a critical organ (retroperitoneal, intracranial, or intraocular), deep hematoma, or overt bleeding associated with a hemoglobin fall of 2 g/dL or more, or leading to transfusion of two or more units of packed red blood cells. The observation period was from the beginning of lepirudin treatment until hospital discharge, which always occurred after cessation of lepirudin treatment. A central independent Critical Event Committee adjudicated all efficacy and safety outcomes. 
Statistical analysis

RESULTS
Patients
The data of 309 patients treated with lepirudin, regardless of the indication, were collected between December 1997 and December 2004 ( Figure 1 ). Among 212 patients with complete data and treated with lepirudin for suspected HIT, the Critical Event Committee confirmed the use of lepirudin for documented HIT in 181 patients who therefore constitute the study
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From population ( Table 1 ). The median age of the population was 67 years; 22.1% of the patients were at least 75 years old. Heparin had been administered within the previous three months in 26.0 % of the patients. Approximately 10% of the patients reported a history of venous thrombosis and 10%, a history of arterial thrombosis. Renal impairment (creatinine clearance of less than 60 mL/min) was observed in 44.7% of the patients.
Heparin-induced thrombocytopenia
The majority of HIT patients (81.2%) received unfractionated heparin alone or associated with a low-molecular-weight heparin at the time of the event ( Table 2 ). Heparin was given at therapeutic doses (i.e. targeting an activated partial thromboplastin time [aPTT] prolongation of 1.5 to 2.5 times baseline value) in 63.5% of the patients. The main indications for heparin therapy were management of cardiac and vascular diseases (37.6%) and venous thromboembolism treatment (22.7%).
HIT occurred after a median of 10.7 days of heparin treatment (Table 3) . Median platelet count fell from 217 Giga/L before heparin therapy to 55 Giga/L just prior to heparin cessation. The fall in platelet count was above 30% of baseline values in 98.9% (178/180) of the cases; blood platelet count was below 100 Giga/L in 88.4% (160/181). Disseminated intravascular coagulation was associated with HIT in 4.4% (8/181) of patients. Diagnosis of HIT was biologically confirmed in 89.5% of patients, primarily by ELISA assay detecting antibodies against heparin-platelet factor 4 complexes. Half of the patients (49.2%) experienced a thrombotic episode, while 6.1 % had a major bleeding event. A third of patients (59 patients, 32.6%) were first treated with danaparoid after heparin discontinuation. This treatment was replaced by lepirudin after a median (Q1-Q3) of 3.3 (1.0-6.5) days because the blood platelet count remained low (61.0%, 36/59), the patient did not show any clinical improvement (44.1%, 26/59), or danaparoid cross-reacted with the patient's heparindependent antibodies (15.3%, 9/59).
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Treatment with lepirudin
Fifty-nine percent (105/178) of patients received a bolus dose of lepirudin at treatment initiation. The mean (± SD) lepirudin dose during the whole treatment period was 0.06 ± 0.04 mg/kg per hour; it ranged from less than 0.04 mg/kg per hour to 0.15 mg/kg per hour in 99.4% of patients (Table 4) During the study period, 13.8% of patients developed a thrombotic episode ( Table 5 ). The median (Q1-Q3) time between initiation of lepirudin therapy and thrombosis was 4 (2) (3) (4) (5) (6) days. The mean dose of lepirudin was 0.08 ± 0.04 mg/kg per hour; the median (Q1-Q3) aPTT prolongation was 2.9 (1.9-6.4) times baseline value.
During the study period, 37 (20.4%) patients presented a major bleed. These occurred during bridging between lepirudin and vitamin K antagonist treatments in 14 patients. Major bleeds were fatal in seven patients (massive hemoptysis in 3 cases, intra-abdominal hemorrhage in 2 cases, intra-thoracic hemorrhage in 1 case and retroperitoneal hemorrhage in 1 case).
Among these seven patients, two patients had disseminated intravascular coagulation, one had For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From received aspirin six days earlier, four had recently undergone major surgery. All but one patient had renal insufficiency and a bolus of lepirudin was administered to three patients. The mean dose of lepirudin was below 0.04 mg/kg per hour in two patients, and between 0.07 and 0.15 mg/kg per hour in four patients; one patient received only one bolus of 0.2 mg/kg. The aPTT was prolonged 2.5 times above baseline value in four patients.
By the end of the study period, 46 (25.4%) patients had died. Six deaths were related to a thrombotic event (Table 5 ) and seven to a major bleed. Among the 33 other patients, HIT was considered to be a major factor of death in 14 patients and a contributing factor in 19 patients.
Predictive factors for thrombosis or major bleeding in HIT patients treated with lepirudin
On multivariate analysis, only administration of therapeutic doses of heparin was a significant positive predictive factor for thrombosis in HIT patients treated with lepirudin (Table 6 ).
Moderate to severe renal impairment, long duration of lepirudin treatment and mean lepirudin dose above 0.07 mg/kg per hour were significant positive factors for major bleeding.
DISCUSSION
The first main finding of this observational study is that, in routine practice, the mean lepirudin dose administered to patients with HIT was lower than the dose recommended in the drug labeling for this indication (i.e. administration of a 0.4 mg/kg bolus dose followed by a continuous intravenous dose of 0.15 mg/kg per hour adjusted to maintain an aPTT between 1.5 and 2.5 times baseline value). Nevertheless, the mean aPTT was above 1.5 times baseline value in almost all patients (98.8%). This result is not entirely explained by the presence of renal impairment in about half of the patients (patients in whom the recommended lepirudin dose is lower 9 ), as the mean lepirudin dose was also low (0.07 mg/kg per hour) in patients with normal creatinine clearance. Moreover, the dose administered steadily diminished
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From between 1997 and 2004, indicating that prescribing practices changed as familiarity with lepirudin treatment increased. Recent studies have also reported that the actual doses administered to HIT patients were lower than those recommended. 8, [10] [11] [12] The second main finding is that, within this low dose range, mean lepirudin dose was nevertheless not an independent predictive factor for thrombotic complications. In contrast, it was an independent predictive factor for major bleeding, i.e. the higher the dose, the higher the bleeding risk. Overall, these results suggest that the dose of lepirudin recommended for HIT patients may be too high and the use of reduced doses may be safer in terms of bleeding risk without compromising the antithrombotic efficacy. Our findings support the recent recommendation proposed by experts of the 2004 ACCP (American College of Chest Physicians) Consensus Conference to use lower lepirudin doses than those indicated in the drug labeling for patients with HIT. 13 These data, reflecting the use of lepirudin in everyday practice, may be compared with those obtained in the most recent prospective controlled study in this setting, i.e. the HeparinAssociated Thrombocytopenia (HAT) -3 study. 8 In this study, the mean lepirudin doses were 0.11 mg/kg per hour in HIT patients with thrombosis and 0.07 mg/kg per hour in asymptomatic HIT patients. Despite the fact that these mean doses were higher than those reported in our study (0.07 and 0.05 mg/kg per hour, respectively), the rates of new thrombotic events and amputations after the initiation of lepirudin are comparable, 11.5%
(20/182) in HAT-3 and 13.8% in our study. In contrast, the risk for thrombosis in HIT patients in whom heparin therapy is discontinued without alternative anticoagulant treatment ranges from 19% to 52%. 14 Thus, although our study was not primarily designed to demonstrate the efficacy of lepirudin, we observe that its result confirm the value of this treatment, even given at doses lower than those recommended. Furthermore, in our study, lepirudin efficacy may have been underestimated, because several patients were first treated with danaparoid, then
For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From switched to lepirudin (for example due to danaparoid inefficacy), suggesting that HIT was particularly severe. Interestingly, in lepirudin-treated patients, previous use of therapeutic doses of unfractionated heparin was an independent predictive factor for thrombotic events. It is indeed possible that HIT patients treated with such heparin doses suffered from a more severe venous thromboembolic disease than patients receiving prophylactic doses of heparin.
The incidence of major bleeding observed in our study (20.4%) is in the upper range of the rates reported in a combined analysis of the three HAT lepirudin studies (17.6%; 95% CI:
14.0 to 21.7). 8 However, the definition of major bleeding used in the present study was broader, also including overt bleeding associated with a fall in hemoglobin of 2 g/dL or more.
In addition, the HAT studies excluded patients with overt signs of bleeding before the start of lepirudin treatment, whereas 6.1% of the patients analyzed in our study exhibited bleeding under heparin therapy. Moreover, the HAT-1 trial excluded patients with renal dysfunction. 6 The fact that moderate or severe renal insufficiency was a predictive factor for major bleeding risk is not surprising, since lepirudin is eliminated primarily through the kidneys. 9 As previously observed, 8, 15 this result emphasizes the importance of careful dosing in patients with renal impairment. Interestingly, as in the recent HAT-3 study, 8 age and sex were not significant risk factors for bleeding.
The limitations of this study are mostly related to its retrospective design, involving collection of data over a relatively long period of time, during which the overall management of HIT patients may have changed. However, the conduct of prospective, randomized, controlled trials in this setting is recognized to be problematic. 14 In addition, we took care to ensure the exhaustiveness of the collection of all cases of lepirudin-treated HIT patients during the study period. Although the diagnosis of HIT was not biologically documented in 10.5% of the patients, it was so adjudicated in all patients by an independent Critical Event Committee on the basis of supporting clinical and/or laboratory data. We therefore believe that our data, obtained in a large number of patients, provide a valid picture of the routine management of HIT patients with lepirudin.
In conclusion, current dosing recommendations for lepirudin in patients with HIT may be too high. If this hypothesis is confirmed in prospective trials, the use of lower but still effective doses of lepirudin in HIT patients may improve the benefit-to-risk ratio of this drug for the management of this complex syndrome.
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